Drimva

GSK

Clinical Biomarker Lead- Oncology Translational Medicine

$151K–$252K

USA - Pennsylvania - Upper Providence +2 · Hybrid (Remote & On-site) · Full-time · Posted Aug 31, 2026

Location
USA - Pennsylvania - Upper Providence
USA - Massachusetts - Waltham
Stevenage
Experience
Ph.D. or equivalent with 3+ years, or M.Sc with 7+ years, of drug development experience.
Education
Ph.D. or equivalent, or M.Sc.

About the job

Leads oncology translational biomarker strategy and collaborative projects to support clinical trials and guide clinical development decisions.

What you'll do

  • Design and manage internal and external projects to develop biomarker capabilities and generate data for clinical trials.
  • Develop and implement biomarker strategies using scientific and technological advances to guide indication selection, patient enrichment, and combination strategies.
  • Coordinate cross-functional biomarker projects and contribute to data reviews, reports, presentations, and scientific publications.

What they ask for

  • Ph.D. or equivalent with 3+ years, or M.Sc with 7+ years, of drug development experience in the pharmaceutical industry; preferably in oncology biomarker development.
  • Experience with biomarker assays, technologies, platforms, and providers, including implementation of platforms such as flow cytometry, NGS, FISH, PCR, and/or IHC/IF in oncology clinical trials.
  • Experience designing and executing translational biomarker strategies in oncology clinical trials, including assay development, validation, sample testing plans, and clinical deployment.
  • Experience delivering clinical biomarker analyses and data packages, managing partner deliverables, timelines, contracts, and budgets, and working to GCP/GLP principles.

Nice to have

  • Experience with high-dimensional dataset analysis.
  • Experience with digital pathology, AI/ML-enabled biomarker analyses, and external scientific partnerships.

Pay

$150,975 to $251,625 (USD, annual base salary)

Tools

flow cytometry, NGS, FISH, PCR, IHC/IF, GCP/GLP, AI/ML

AI focus

Experience with AI/ML-enabled biomarker analyses is preferred.

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 6, 2026 (UTC)